HOME
ABOUT US
STRATEGY
TEAM
PORTFOLIO
4BATLE ICAV
NEWSROOM
CONTACT
More
FDA Approves Spark Therapeutics’ LUXTURNA™ (voretigene neparvovec-rzyl)